Dong-A ST Co., Ltd.

CompanySouth Korea

Dong-A ST Co., Ltd. develops 2 assets, the furthest approved (celecoxib in acute pain). Mostly small molecule acting on inflammation, PTGS2 and OPRM1; based in South Korea.

Assets
2
Furthest
Approved
Trials
17
Signals
1

Pipeline

2

  • celecoxib

    Selective cyclooxygenase-2 inhibitor reducing prostaglandin synthesis to relieve pain and inflammation

    ApprovedSmall moleculeInflammationPTGS2acute painadenomatous polyposis coli

  • rosuvastatin

    HMG-CoA reductase inhibitor lowering LDL cholesterol.

    ApprovedSmall moleculeLipid and ceramide metabolismSLC5A2acute coronary syndrome (Phase 3)atherosclerosis (Phase 3)

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms7
  • Trials20
  • Signals4
  • Similar companies6

Updated 7 Oct 2026 · 157 sources

Intelligence